ESSA Pharma (NASDAQ:EPIX) Versus Alnylam Pharmaceuticals (NASDAQ:ALNY) Head to Head Comparison
ESSA Pharma (NASDAQ:EPIX) Versus Alnylam Pharmaceuticals (NASDAQ:ALNY) Head to Head Comparison
ESSA Pharma (NASDAQ:EPIX – Get Rating) and Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, valuation, institutional ownership, earnings and dividends.
埃萨制药(纳斯达克：EPIX-GET评级)和艾尼兰制药(纳斯达克：ALNY-GET评级)都是医疗公司，但哪一项投资更好？我们将根据这两家公司的风险强度、分析师建议、盈利能力、估值、机构所有权、收益和股息对这两家公司进行对比。
Analyst Ratings
分析师评级
This is a summary of recent ratings for ESSA Pharma and Alnylam Pharmaceuticals, as provided by MarketBeat.com.
这是由MarketBeat.com提供的ESSA Pharma和Alnylam PharmPharmticals最近的评级摘要。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ESSA Pharma | 0 | 0 | 0 | 0 | N/A |
| Alnylam Pharmaceuticals | 0 | 5 | 12 | 0 | 2.71 |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| Essa Pharma | 0 | 0 | 0 | 0 | 不适用 |
| Alnylam制药公司 | 0 | 5 | 12 | 0 | 2.71 |
ESSA Pharma presently has a consensus price target of $20.00, indicating a potential upside of 998.90%. Alnylam Pharmaceuticals has a consensus price target of $232.06, indicating a potential upside of 12.44%. Given ESSA Pharma's higher probable upside, research analysts clearly believe ESSA Pharma is more favorable than Alnylam Pharmaceuticals.
Essa Pharma目前的共识目标价为20.00美元，表明潜在上涨998.90%。Alnylam PharmPharmticals的共识目标价为232.06美元，表明潜在涨幅为12.44%。鉴于ESSA Pharma的上行可能性更高，研究分析师显然认为ESSA Pharma比Alnylam PharmPharmticals更有利。
Volatility & Risk
波动性与风险
Profitability
盈利能力
This table compares ESSA Pharma and Alnylam Pharmaceuticals' net margins, return on equity and return on assets.
此表比较了ESSA Pharma和Alnylam PharmPharmticals的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| ESSA Pharma | N/A | -20.39% | -19.95% |
| Alnylam Pharmaceuticals | -110.91% | -204.18% | -28.26% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| Essa Pharma | 不适用 | -20.39% | -19.95% |
| Alnylam制药公司 | -110.91% | -204.18% | -28.26% |
Earnings & Valuation
收益与估值
This table compares ESSA Pharma and Alnylam Pharmaceuticals' revenue, earnings per share and valuation.
该表格比较了ESSA Pharma和Alnylam PharmPharmticals的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ESSA Pharma | N/A | N/A | -$36.81 million | ($0.86) | -2.12 |
| Alnylam Pharmaceuticals | $844.29 million | 29.34 | -$852.82 million | ($8.17) | -25.26 |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| Essa Pharma | 不适用 | 不适用 | -3,681万元 | ($0.86) | -2.12 |
| Alnylam制药公司 | 8.4429亿美元 | 29.34 | -8.5282亿美元 | ($8.17) | -25.26 |
ESSA Pharma has higher earnings, but lower revenue than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than ESSA Pharma, indicating that it is currently the more affordable of the two stocks.
Essa Pharma的收益高于Alnylam PharmPharmticals，但营收低于Alnylam PharmPharmticals。Alnylam PharmPharmticals的市盈率低于ESSA Pharma，这表明它目前是两只股票中更负担得起的一只。
Insider & Institutional Ownership
内部人与机构所有权
93.2% of Alnylam Pharmaceuticals shares are held by institutional investors. 9.9% of ESSA Pharma shares are held by insiders. Comparatively, 1.4% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Alnylam PharmPharmticals 93.2%的股份由机构投资者持有。ESSA Pharma 9.9%的股份由内部人士持有。相比之下，Alnylam PharmPharmticals 1.4%的股份由内部人士持有。强大的机构持股表明，对冲基金、捐赠基金和大型基金管理公司相信，一家公司有望实现长期增长。
Summary
摘要
ESSA Pharma beats Alnylam Pharmaceuticals on 9 of the 12 factors compared between the two stocks.
Essa Pharma在两只股票比较的12个因素中有9个击败了Alnylam PharmPharmticals。
About ESSA Pharma
关于ESSA Pharma
(Get Rating)
(获取评级)
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Essa Pharma Inc.是一家临床阶段制药公司，专注于开发治疗前列腺癌的新型专利疗法。它开发了EPI-7386，这是一种口服候选药物，正在进行I期临床研究，用于治疗转移性去势抵抗前列腺癌患者。该公司与Caris Life Science，Inc.，Bayer Consumer Care AG，Janssen Research&Development，LLC和Astellas Pharma Inc.签订了合作协议。Essa Pharma Inc.成立于2009年，总部设在加拿大温哥华。
About Alnylam Pharmaceuticals
关于Alnylam制药公司
(Get Rating)
(获取评级)
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Alnylam制药公司是一家生物制药公司，专注于发现、开发和商业化基于核糖核酸干扰的新型疗法。该公司的研究RNAi疗法流水线专注于遗传药物、心脏代谢疾病、肝脏传染病和中枢神经系统(CNS)/眼睛疾病。其销售的产品包括ONPATTRO(PATSIRAN)，一种用于治疗成人遗传性甲状腺激素介导的淀粉样变性多发性神经病的脂质复合注射剂；GIVLAARI，用于治疗成人急性肝性卟啉(AHP)；以及OXLUMO(LUMASHRAN)，用于治疗原发性高草酸尿症1型(PH1)。此外，该公司正在开发吉沃西兰，用于治疗患有AHP的青少年患者；PATSIRAN，用于治疗伴心肌病的甲状旁腺素淀粉样变性，或ATTR淀粉样变性；西地西兰，用于治疗补体介导的疾病；ALN-AAT02，用于治疗AAT缺乏相关的肝病；ALN-HBV02，用于治疗慢性乙肝感染；Zilebesiran，用于治疗高血压；以及ALN-HSD，用于治疗NASH。此外，它还提供Fitusiran用于治疗血友病和罕见的出血性疾病，Inclisiran用于治疗高胆固醇血症，Lumasiran用于治疗晚期PH1和复发性肾结石，vutrisiran用于治疗正处于第三阶段临床试验的ATTR淀粉样变性。Alnylam制药公司与Regeneron制药公司有战略合作，通过解决在眼睛和中枢神经系统中表达的治疗靶点来发现、开发和商业化针对一系列疾病的RNAi疗法；赛诺菲Genzyme公司发现、开发RNAi疗法并将其商业化。它还与诺华制药、Vir生物技术公司、Dicerna制药公司、爱奥尼斯制药公司和PeptiDream公司签订了许可和合作协议, 该公司成立于2002年，总部设在马萨诸塞州剑桥市。
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受ESSA Pharma Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对ESSA Pharma和相关公司的最新新闻和分析师评级的每日简要摘要。